Skip to content Skip to footer
Subscribe Now
INSIGHTS+

EMA Marketing Authorization of New Drugs in January 2026    

Shots:  The European Commission approved multiple therapies across vaccines, rare diseases, endocrinology, and immunology, including products from BioNet, Sanofi, Fondazione Telethon, IntraBio, and Ionis / Otsuka.  The Committee for Medicinal Products for Human Use also issued positive opinions for late-stage assets from UCB and Gedeon Richter, with additional recommendations supporting Sanofi’s Rezurock.  Decisions were backed by strong Phase II/III data…
February 17, 2026

Read more

NEWS

BioNet’s VacPertagen Receives the EC Approval for Pertussis Disease 

Shots:  The EC has approved VacPertagen as a booster aganist Pertussis for pts (age≥12) and for passive infant protection via maternal immunization during pregnancy     CHMP recommendation was supported by data from three clinical trials and nine supportive studies, all consistently demonstrating that VacPertagen is safe for use in teenagers, adults, and pregnant women across populations  VacPertagen is an acellular pertussis vaccine with two components, including recombinant…
January 9, 2026

Read more

NEWS

BioNet’s VacPertagen Receives the CHMP’s Positive Opinion for Pertussis Disease 

Shots:  The CHMP has recommended VacPertagen as a booster aganist Pertussis for pts (age≥12) and for passive infant protection via maternal immunization during pregnancy   VacPertagen is an acellular pertussis vaccine with two components, including recombinant Pertussis Toxin (PTgen) and filamentous haemagglutinin (FHA), providing targeted protection without unnecessary antigens   VacPertagen’s benefits have been demonstrated in three clinical studies involving adults, adolescents, and pregnant women  Ref: BioNet| Image: BioNet| Press Release…
November 13, 2025

Read more